215 related articles for article (PubMed ID: 38494768)
1. [Advances in the treatment of anti-HER-2 antibody drug conjugates in pan-tumor with low HER-2 expression].
Wei T; Yuan P
Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(3):211-220. PubMed ID: 38494768
[TBL] [Abstract][Full Text] [Related]
2. Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.
Yu J; Wu S; Li R; Jiang Y; Zheng J; Li Z; Li M; Xin K; Guan X; Li S; Chen X
J Hematol Oncol; 2023 Jul; 16(1):85. PubMed ID: 37507780
[TBL] [Abstract][Full Text] [Related]
3. A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.
Kim JH; Chang IH
Investig Clin Urol; 2022 Jul; 63(4):373-384. PubMed ID: 35670004
[TBL] [Abstract][Full Text] [Related]
4. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions.
Yu J; Li M; Liu X; Wu S; Li R; Jiang Y; Zheng J; Li Z; Xin K; Xu Z; Li S; Chen X
Biomed Pharmacother; 2024 May; 174():116522. PubMed ID: 38565055
[TBL] [Abstract][Full Text] [Related]
5. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug conjugates in HER2-positive breast cancer.
Li L; Zhang D; Liu B; Lv D; Zhai J; Guan X; Yi Z; Ma F
Chin Med J (Engl); 2021 Dec; 135(3):261-267. PubMed ID: 34935688
[TBL] [Abstract][Full Text] [Related]
7. The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma.
Abel M; Burkenroad A; Sun A; Lu E; Stefanoudakis D; Drakaki A
Clin Genitourin Cancer; 2021 Jun; 19(3):183-193. PubMed ID: 33558159
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates for urothelial carcinoma.
Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
[TBL] [Abstract][Full Text] [Related]
9. Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors.
McNamara B; Greenman M; Pebley N; Mutlu L; Santin AD
Molecules; 2023 Nov; 28(21):. PubMed ID: 37959808
[TBL] [Abstract][Full Text] [Related]
10. Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope.
Yamaguchi A; Anami Y; Ha SYY; Roeder TJ; Xiong W; Lee J; Ueno NT; Zhang N; An Z; Tsuchikama K
Bioorg Med Chem; 2021 Feb; 32():116013. PubMed ID: 33482584
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors.
Kalinovsky DV; Kibardin AV; Kholodenko IV; Svirshchevskaya EV; Doronin II; Konovalova MV; Grechikhina MV; Rozov FN; Larin SS; Deyev SM; Kholodenko RV
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764367
[TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
13. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.
Wong JL; Rosenberg JE
Expert Opin Biol Ther; 2021 Jul; 21(7):863-873. PubMed ID: 34030536
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment.
Deng S; Lin Z; Li W
Curr Med Chem; 2017; 24(23):2505-2527. PubMed ID: 28554322
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
Lambert JM; Morris CQ
Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
[TBL] [Abstract][Full Text] [Related]
16. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
[TBL] [Abstract][Full Text] [Related]
18. [Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer].
Wang N; Zhao L; Zhang D; Jia Y; Kong F
Zhongguo Fei Ai Za Zhi; 2022 Mar; 25(3):214-218. PubMed ID: 35340165
[TBL] [Abstract][Full Text] [Related]
19. Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
Nicolò E; Repetto M; Boscolo Bielo L; Tarantino P; Curigliano G
Cancer J; 2022 Nov-Dec 01; 28(6):436-445. PubMed ID: 36383906
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Resistance to Antibody-Drug Conjugates.
Khoury R; Saleh K; Khalife N; Saleh M; Chahine C; Ibrahim R; Lecesne A
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]